Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Syndax Pharmaceuticals, Inc. (SNDX : NSDQ)

• Company Description    Syndax Pharmaceuticals, Inc. is a biopharmaceutical company which focused on the development and commercialization of entinostat, an epigenetic therapy for treatment-resistant cancers. The Company's product pipeline includes ENCORE 601, ENCORE 602, J1353, NCI-7870, NCI-9844, E2112, NCI-8871 and NCI-9253 which are in clinical trial stage. Syndax Pharmaceuticals, Inc. is based in WALTHAM, United States. Number of Employees: 270

• Price / Volume Information    Yesterday's Closing Price: $13.70 Daily Weekly Monthly 20 Day Moving Average: 3,406,448 shares Shares Outstanding: 86.14 (millions) Market Capitalization: $1,180.15 (millions) Beta: 0.68 52 Week High: $22.50 52 Week Low: $8.58 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -11.27% -12.89% 12 Week 7.70% -0.17% Year To Date 3.63% -12.68%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 730 Third Avenue 9th Floor - New York,NY 10017 USA ph: 781-419-1400 fax: 781-419-1420 ir@syndax.com http://www.syndax.com

• General Corporate Information    Officers Michael A. Metzger - Chief Executive Officer and Director Dennis G. Podlesak - Chairman Keith A. Goldan - Chief Financial Officer Martin H. Huber - Director Jennifer Jarrett - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 87164F105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/03/25 Share - Related Items Shares Outstanding: 86.14 Most Recent Split Date: (:1) Beta: 0.68 Market Capitalization: $1,180.15 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.52 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.24 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 31.23% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/03/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 7.49 Price/Cash Flow: - Price / Sales: 15.10 EPS Growth vs. Year Ago Period: -3.75% vs. Previous Quarter: 15.31% Sales Growth vs. Year Ago Period: 984.51% vs. Previous Quarter: 89.39% ROE 09/30/25 - - 06/30/25 - -130.47 03/31/25 - -101.60 ROA 09/30/25 - - 06/30/25 - -56.12 03/31/25 - -58.41 Current Ratio 09/30/25 - - 06/30/25 - 4.71 03/31/25 - 5.80 Quick Ratio 09/30/25 - - 06/30/25 - 4.55 03/31/25 - 5.75 Operating Margin 09/30/25 - - 06/30/25 - -428.48 03/31/25 - -757.53 Net Margin 09/30/25 - - 06/30/25 - -428.48 03/31/25 - -757.53 Pre-Tax Margin 09/30/25 - - 06/30/25 - -428.48 03/31/25 - -757.52 Book Value 09/30/25 - - 06/30/25 - 1.83 03/31/25 - 2.50 Inventory Turnover 09/30/25 - - 06/30/25 - 0.53 03/31/25 - 1.36 Debt-to-Equity 09/30/25 - - 06/30/25 - 2.06 03/31/25 - 1.53 Debt-to-Capital 09/30/25 - - 06/30/25 - 67.33 03/31/25 - 60.52

Powered by Zacks Investment Research ©